Recently, clinical and basic research on CAR T-cell treatment for MM has started to yield encouraging results and, among the MM-specific targets current under investigation, B-cell maturation antigen (BCMA) seems to be the most promising one (187). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.